We would love to hear your thoughts about our site and services, please take our survey here.
Xnoz, this is argueably the best entry point there's ever been for AVCT. Not the cheapest the share price has been, but certainly very favourable in terms of share price vs proxmity to signicant news.
The current price is not great for us LTH's who have seen a chunk of their paper profits vanish, and even worse for those who arived a little later who are underwater. Regardless, the outlook here is very good at present IMO.
Great post bottomzup. The information we have is only speculation based on the crumbs everybody has been able to piece together, but nevertheless I very much agree with your outlook on this share.
Big Al said Q4 supposed to be transformational. Not much of it left now...
As much as I would like to see some FOMO building, I don't think that's going to happen as there's not much confidence in the bloke until he actually delivers something.
Saying summer was foolish. Missing that timeframe and then saying Q4 and missing that too would be idiotic and to be honest, completely disrepectful to shareholders unless some some of update or reasoning is provided.
I personally think we will get a decent RNS before the end of the year, but I'm probably on 60/40 on that. Lets see.
Great post Alastair.
I've thought many times about selling out. The delays have been a poor show and I think we all feel we have been mislead. If you look at the RNS log it doesn't appear that's the case, but for those of us who have watched and heard all the interviews there's just no getting away from it.
What keeps me on board is that I don't want to repeat a mistake I've made too many times in the past... That is... Losing my nerve and jumping ship,only to watch the share price subsequently take off.
I've lucky to have never made a significant loss from a share, but I've certainly missed out on a lot of profits by bailing out early.
Until an RNS tells us something bad has happened I am in. BAMS and ELISA work, we know that. The LFT should therefore be good too, although late to the party. The chances of bad news are very low IMO, but the slowness to market is super frustrating as we see competitors make money we thought would be ours.
Been here about 8 or 9 months now. Not going anywhere yet.
From Reuters:
Global demand for COVID-19 testing devices is expected to outstrip supply for a long time, Roche Chief Executive Severin Schwan said on Tuesday.
“We still have little information about duration and efficacy of vaccines (...) So diagnostics will remain very important, not only for the months to come but the years to come,” Schwan said in a briefing of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
I'm looking for 1200 or results rns (whichever comes first) and then I'll be selling and moving on. I think that will be fairly soon. I'm sure it will go much further, but at that point I'll sit on the sidelines and see how it plays out.
Something which I find baffling is how quickly the Government can decide it's safe to start injecting it's population with a new type of vaccine with no long term data on side effects... but how long it takes to simply validate a test.
It's either funny or terrifying.
Well said. Company communication is poor at best. Let's hope they pull something good out the bag soon.
Despite the very long wait and bumps in the road, I remain very positive and mostly for one single reason...
Avacta simply CANNOT afford to balls this up.
Failure to deliver will destry Sir Als credibility. Current issues such as the change to swab and his house buying can be forgiven, but a total failure cannot.
Secondly, delivery of a test which is anything less than excellent will destroy the belief in Affimers - the core of the company.
Failure is simply not an option here.
TWatcher, the type of nasal swab is very important. Nasopharyngeal is very unpleasant and not ideal for a product being used by the consumer. Anterior nasal is just the accessible part of your nose and therefore not painful or unpleasant. Anterior will have the much larger uptake imo, won't be easy to get the public doing it otherwise.
Somebody please correct me if I'm wrong but I understand as follows:
Innova is anterior swab
Roche is nasopharyngeal
Avacta is working on both anterior swab and on saliva
ISH is nasopharyngeal
There's been a lot of posts over the last few months saying just get a test out there and refine it later. I think we can all see now why thats not a good idea. I don't like the slowness either, but it's certainly preferable to the sh*t show which would follow if it's weren't done right...
Fardistanthills, I agree with you and posted similar. Any good news would be significantly tainted by it being a swab without the market having sufficient time to absorb that information beforehand.